CA2110291A1 - Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers - Google Patents

Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers

Info

Publication number
CA2110291A1
CA2110291A1 CA002110291A CA2110291A CA2110291A1 CA 2110291 A1 CA2110291 A1 CA 2110291A1 CA 002110291 A CA002110291 A CA 002110291A CA 2110291 A CA2110291 A CA 2110291A CA 2110291 A1 CA2110291 A1 CA 2110291A1
Authority
CA
Canada
Prior art keywords
anionic polymers
anionic
methods
preferred
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002110291A
Other languages
French (fr)
Other versions
CA2110291C (en
Inventor
Dikla Roufa
Adrian Harel
Robert C.A. Frederickson
George T. Coker, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wright Medical Technology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2110291A1 publication Critical patent/CA2110291A1/en
Application granted granted Critical
Publication of CA2110291C publication Critical patent/CA2110291C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/857—Fish; fish eggs; shell fish; crustacea
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915—Method or apparatus for preparing biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/924—Material characteristic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/789—Of specified organic or carbon-based composition in array format
    • Y10S977/79—Of specified organic or carbon-based composition in array format with heterogeneous nanostructures
    • Y10S977/791—Molecular array
    • Y10S977/793—Protein array
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/91—Strengthening cell or tissue

Abstract

The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus, the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion.
Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10 % by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.
CA002110291A 1991-05-31 1992-05-29 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers Expired - Lifetime CA2110291C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US708,660 1991-05-31
US07/708,660 US5605938A (en) 1991-05-31 1991-05-31 Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
PCT/US1992/004474 WO1992021354A1 (en) 1991-05-31 1992-05-29 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers

Publications (2)

Publication Number Publication Date
CA2110291A1 true CA2110291A1 (en) 1992-12-10
CA2110291C CA2110291C (en) 2009-10-13

Family

ID=24846689

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002110291A Expired - Lifetime CA2110291C (en) 1991-05-31 1992-05-29 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers

Country Status (19)

Country Link
US (8) US5605938A (en)
EP (3) EP0586535B1 (en)
JP (6) JP3379757B2 (en)
KR (1) KR100237731B1 (en)
AT (3) ATE297212T1 (en)
AU (1) AU671256B2 (en)
BG (1) BG98333A (en)
BR (1) BR9206077A (en)
CA (1) CA2110291C (en)
CZ (1) CZ259493A3 (en)
DE (5) DE69233753D1 (en)
DK (1) DK0586535T3 (en)
ES (3) ES2151887T3 (en)
FI (1) FI935345A (en)
GR (3) GR3034760T3 (en)
HU (1) HUT66427A (en)
NO (1) NO305974B1 (en)
SK (1) SK134393A3 (en)
WO (1) WO1992021354A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68922497T2 (en) * 1988-08-24 1995-09-14 Marvin J Slepian ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS.
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US6352707B1 (en) 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
IT1259090B (en) * 1992-04-17 1996-03-11 Fidia Spa BIOMATERIALS FOR BONE PROSTHESIS
DE69414558T2 (en) * 1993-03-23 1999-07-15 Focal Inc DEVICE AND METHOD FOR LOCAL APPLICATION OF POLYMER MATERIAL ON FABRIC
US5665063A (en) * 1994-06-24 1997-09-09 Focal, Inc. Methods for application of intraluminal photopolymerized gels
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US6514289B1 (en) 2000-01-30 2003-02-04 Diamicron, Inc. Diamond articulation surface for use in a prosthetic joint
US6800095B1 (en) 1994-08-12 2004-10-05 Diamicron, Inc. Diamond-surfaced femoral head for use in a prosthetic joint
US6425922B1 (en) 2000-01-30 2002-07-30 Diamicron, Inc. Prosthetic hip joint having at least one sintered polycrystalline diamond compact articulation surface
US6596225B1 (en) 2000-01-31 2003-07-22 Diamicron, Inc. Methods for manufacturing a diamond prosthetic joint component
US6676704B1 (en) 1994-08-12 2004-01-13 Diamicron, Inc. Prosthetic joint component having at least one sintered polycrystalline diamond compact articulation surface and substrate surface topographical features in said polycrystalline diamond compact
US7396505B2 (en) * 1994-08-12 2008-07-08 Diamicron, Inc. Use of CoCrMo to augment biocompatibility in polycrystalline diamond compacts
US6494918B1 (en) 2000-01-30 2002-12-17 Diamicron, Inc. Component for a prosthetic joint having a diamond load bearing and articulation surface
US6402787B1 (en) 2000-01-30 2002-06-11 Bill J. Pope Prosthetic hip joint having at least one sintered polycrystalline diamond compact articulation surface and substrate surface topographical features in said polycrystalline diamond compact
US5931165A (en) * 1994-09-06 1999-08-03 Fusion Medical Technologies, Inc. Films having improved characteristics and methods for their preparation and use
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US5779673A (en) * 1995-06-26 1998-07-14 Focal, Inc. Devices and methods for application of intraluminal photopolymerized gels
JP2000510720A (en) * 1996-05-03 2000-08-22 ユーロス コーポレイション Pentosan polysulfate coating for medical devices
US5791352A (en) * 1996-06-19 1998-08-11 Fusion Medical Technologies, Inc. Methods and compositions for inhibiting tissue adhesion
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
EP0927196B1 (en) * 1996-09-19 2008-11-05 The Regents Of The University Of Michigan Polymers containing polysaccharides such as alginates or modified alginates
US20090324721A1 (en) 1996-09-23 2009-12-31 Jack Kennedy Hydrogels Suitable For Use In Polyp Removal
US7009034B2 (en) * 1996-09-23 2006-03-07 Incept, Llc Biocompatible crosslinked polymers
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6566406B1 (en) * 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
US6206917B1 (en) * 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
US6018035A (en) * 1997-07-21 2000-01-25 Baxter International Inc. Reagents for isotropic size enhancement of a peptide, protein, nucleotide or other substrate
US5981710A (en) * 1997-07-21 1999-11-09 Baxter International, Inc. Therapeutic hemoglobin composition having isotropically increased size
US6204254B1 (en) 1997-09-12 2001-03-20 Baxter International, Inc. Biocompatible surfaces and a method for their preparation
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
AU1214999A (en) * 1998-01-22 1999-08-12 Seikagaku Corporation Antifibrotic agent
US6872384B1 (en) 1998-02-23 2005-03-29 Life Medical Sciences, Inc. Treatment of trauma
GB9810127D0 (en) 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6514534B1 (en) * 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
KR20020000143A (en) 1999-02-23 2002-01-04 페어슨 메디칼 인크. Treatment of Trauma
WO2000052516A2 (en) 1999-03-01 2000-09-08 Boston Innovative Optics, Inc. System and method for increasing the depth of focus of the human eye
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
EP1459757A1 (en) * 1999-04-02 2004-09-22 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6942695B1 (en) 1999-04-05 2005-09-13 Wessley-Jessen Corporation Biomedical devices with polyimide coating
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
FR2793693A3 (en) * 1999-05-18 2000-11-24 Martine Bulette Vascular prosthesis is made of base material, optionally textile, impregnated with bio-polymer of vegetable origin to make it impermeable to blood
WO2001045577A2 (en) * 1999-12-06 2001-06-28 Sdgi Holdings, Inc. Intervertebral disc treatment devices and methods
US20020010140A1 (en) 2000-01-19 2002-01-24 Striker Gary E. Use of pentosan polysulfate to treat certain conditions of the prostate
KR100740735B1 (en) * 2000-01-21 2007-07-19 이노바타 피엘씨 Dextrin containing compositions for prevention of adhesions
US6709463B1 (en) 2000-01-30 2004-03-23 Diamicron, Inc. Prosthetic joint component having at least one solid polycrystalline diamond component
US6488715B1 (en) 2000-01-30 2002-12-03 Diamicron, Inc. Diamond-surfaced cup for use in a prosthetic joint
US6410877B1 (en) 2000-01-30 2002-06-25 Diamicron, Inc. Methods for shaping and finishing prosthetic joint components including polycrystalline diamond compacts
EP1645248B8 (en) * 2000-02-04 2010-06-16 Warsaw Orthopedic, Inc. Expandable interbody spinal fusion implant having pivotally attached blocker
US6500205B1 (en) * 2000-04-19 2002-12-31 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with cylindrical configuration during insertion
US6814756B1 (en) * 2000-02-04 2004-11-09 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with lordotic configuration during insertion
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
KR100338491B1 (en) * 2000-03-30 2002-05-30 채수경 Polyphosphate as promoter for recovery of wound and restraint of scar
EP1289537B1 (en) 2000-05-31 2005-11-30 Encelle, Inc. Method of treating chronic ulcers
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US20030007951A1 (en) * 2000-08-23 2003-01-09 Richard Franklin Treatment of trauma
SV2003000753A (en) 2000-12-05 2003-06-16 Brigham & Womens Hospital USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
US7118579B2 (en) * 2001-02-04 2006-10-10 Sdgi Holdings, Inc. Instrumentation for inserting an expandable interbody spinal fusion implant
CA2443425C (en) * 2001-06-04 2009-09-15 Gary Karlin Michelson Dynamic anterior cervical plate system having moveable segments and instrumentation therefor
WO2002098277A2 (en) * 2001-06-04 2002-12-12 Michelson Gary K Anterior cervical plate system having vertebral body engaging anchors, connecting plate, and method for installation thereof
US7097645B2 (en) * 2001-06-04 2006-08-29 Sdgi Holdings, Inc. Dynamic single-lock anterior cervical plate system having non-detachably fastened and moveable segments
US7186256B2 (en) * 2001-06-04 2007-03-06 Warsaw Orthopedic, Inc. Dynamic, modular, single-lock anterior cervical plate system having assembleable and movable segments
US7044952B2 (en) * 2001-06-06 2006-05-16 Sdgi Holdings, Inc. Dynamic multilock anterior cervical plate system having non-detachably fastened and moveable segments
US7041105B2 (en) * 2001-06-06 2006-05-09 Sdgi Holdings, Inc. Dynamic, modular, multilock anterior cervical plate system having detachably fastened assembleable and moveable segments
US8101196B2 (en) 2001-06-26 2012-01-24 Biointeractions, Ltd. Polysaccharide biomaterials and methods of use thereof
US7618937B2 (en) * 2001-07-20 2009-11-17 Northwestern University Peptidomimetic polymers for antifouling surfaces
US7858679B2 (en) * 2001-07-20 2010-12-28 Northwestern University Polymeric compositions and related methods of use
US8815793B2 (en) * 2001-07-20 2014-08-26 Northwestern University Polymeric compositions and related methods of use
US20050203578A1 (en) * 2001-08-15 2005-09-15 Weiner Michael L. Process and apparatus for treating biological organisms
US20070238697A1 (en) * 2001-08-29 2007-10-11 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
DE60232688D1 (en) * 2001-11-20 2009-07-30 Univ Duke BOUNDARY-BIOMATERIALS
US20080086792A1 (en) 2006-10-13 2008-04-17 Thomas Charles Kuracina Method and apparatus for diverting sweat, liquid, moisture or the like from an eye
JP4624678B2 (en) 2002-02-21 2011-02-02 パイオニア・サージカル・オーソバイオロジックス，インコーポレイテッド Cross-linked bioactive hydrogel matrix
CA2419831A1 (en) * 2002-02-28 2003-08-28 Macropore Biosurgery, Inc. Methods for governing bone growth
WO2003104423A2 (en) * 2002-06-11 2003-12-18 Roy Ogle Meningeal-derived stem cells
US8911831B2 (en) * 2002-07-19 2014-12-16 Northwestern University Surface independent, surface-modifying, multifunctional coatings and applications thereof
US20080171012A1 (en) * 2007-01-11 2008-07-17 Phillip Messersmith Fouling Resistant Coatings and Methods of Making Same
EP1539262A1 (en) * 2002-07-29 2005-06-15 Potencia Medical AG Durable implant
CA2495818A1 (en) * 2002-08-20 2004-03-04 John N. Semertzides Compositions comprising epithelial cells for the treatment and prevention of tissue adhesions
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US20040054414A1 (en) * 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
US7217254B2 (en) 2002-09-20 2007-05-15 Genzyme Corporation Multi-pressure biocompatible agent delivery device and method
US20040127416A1 (en) * 2002-11-15 2004-07-01 Massia Stephen P. Therapeutic bioconjugates
JP2006515765A (en) 2002-11-15 2006-06-08 エスディージーアイ・ホールディングス・インコーポレーテッド Collagen-based materials and methods for treating synovial joints
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
US20040219160A1 (en) * 2003-03-31 2004-11-04 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
ITMI20031023A1 (en) 2003-05-21 2004-11-22 Umberto Cornelli GLYCOSAMINOGLICANS WITH AVERAGE MOLECULAR WEIGHT 2400 D AT THE TREATMENT OF EMOTIONAL DYSFUNCTIONS.
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
WO2004105737A2 (en) * 2003-05-30 2004-12-09 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2005000331A2 (en) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US20050046794A1 (en) * 2003-06-17 2005-03-03 Silvestrini Thomas A. Method and apparatus for aligning a mask with the visual axis of an eye
EP1643969A2 (en) * 2003-07-11 2006-04-12 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
UA91818C2 (en) * 2003-08-14 2010-09-10 Уайт Recombinant lubricin molecules and uses thereof
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US20050095219A1 (en) * 2003-10-29 2005-05-05 Shu-Ping Yang Compositions for promoting vaginal cell proliferation and maturation
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005054446A2 (en) * 2003-12-02 2005-06-16 Universiteit Gent Use of polysulphated alginate in cellular matrices
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CA2563347C (en) 2004-04-20 2014-01-14 Genzyme Corporation Surgical mesh-like implant
US20090155200A1 (en) * 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
SE0401069D0 (en) * 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7794490B2 (en) * 2004-06-22 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices with antimicrobial and biodegradable matrices
DE102004031258A1 (en) * 2004-06-29 2006-02-09 Jennissen, Herbert P., Prof. Dr. Protein hybrids with polyhydroxyaromatic amino acid epitopes
US20060009839A1 (en) * 2004-07-12 2006-01-12 Scimed Life Systems, Inc. Composite vascular graft including bioactive agent coating and biodegradable sheath
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
JP2008507553A (en) * 2004-07-23 2008-03-13 ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー Compositions and methods for viscous replenishment
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2006032144A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
WO2006060473A2 (en) * 2004-12-03 2006-06-08 Mucosal Therapeutics Llc Methods of treatment of injured or diseased joints with lubricin compositions
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8257438B2 (en) * 2005-04-12 2012-09-04 Warsaw Orthopedic, Inc. Methods and devices for preserving motion in an articulating prosthetic disc
US7976577B2 (en) * 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
WO2006111348A1 (en) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US20070031498A1 (en) * 2005-08-02 2007-02-08 Wright Medical Technology, Inc. Gel composition for cellular adhesion inhibition
WO2007026362A2 (en) * 2005-09-02 2007-03-08 Colbar Lifescience Ltd. Cross-linked polysaccharide and protein matrices and methods for their preparation
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
JP4732881B2 (en) * 2005-12-07 2011-07-27 Ｔｔｉ・エルビュー株式会社 Iontophoresis device
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US7732539B2 (en) * 2006-02-16 2010-06-08 National Science Foundation Modified acrylic block copolymers for hydrogels and pressure sensitive wet adhesives
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
TWI436793B (en) 2006-08-02 2014-05-11 Baxter Int Rapidly acting dry sealant and methods for use and manufacture
US7622533B2 (en) 2006-08-04 2009-11-24 Nerites Corporation Biomimetic compounds and synthetic methods therefor
WO2008091386A2 (en) * 2006-08-04 2008-07-31 Northwestern University Biomimetic modular adhesive complex: material, methods and applications therefore
US20080069855A1 (en) * 2006-08-21 2008-03-20 Bonutti Peter M Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss
US8383092B2 (en) * 2007-02-16 2013-02-26 Knc Ner Acquisition Sub, Inc. Bioadhesive constructs
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US20090068247A1 (en) * 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US9308068B2 (en) 2007-12-03 2016-04-12 Sofradim Production Implant for parastomal hernia
WO2009108760A2 (en) 2008-02-26 2009-09-03 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
EP2095832A1 (en) * 2008-02-28 2009-09-02 Bayer MaterialScience AG Post-operative adhesion barriers
WO2009109194A2 (en) 2008-02-29 2009-09-11 Ferrosan A/S Device for promotion of hemostasis and/or wound healing
US9242026B2 (en) 2008-06-27 2016-01-26 Sofradim Production Biosynthetic implant for soft tissue repair
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
CA2753698C (en) * 2009-02-17 2015-01-06 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
US9566297B2 (en) * 2009-02-17 2017-02-14 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
US8545459B2 (en) * 2009-02-25 2013-10-01 Teleflex Medical Incorporated Stabilized enzyme compositions
US9333280B2 (en) 2009-02-25 2016-05-10 Teleflex Medical Incorporated Stabilized enzyme compositions
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
PT2442835E (en) 2009-06-16 2015-03-23 Baxter Healthcare Sa Hemostatic sponge
JO3676B1 (en) * 2009-07-27 2020-08-27 Arc Medical Devices Inc Pharmaceutical compositions comprising modified fucans and methods relating thereto
CA2770735C (en) 2009-08-13 2017-07-18 Acufocus, Inc. Masked intraocular implants and lenses
FR2949688B1 (en) 2009-09-04 2012-08-24 Sofradim Production FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER
USD656526S1 (en) 2009-11-10 2012-03-27 Acufocus, Inc. Ocular mask
US20110130465A1 (en) * 2009-12-01 2011-06-02 Nerites Corporation Coatings for prevention of biofilms
GB0921460D0 (en) 2009-12-08 2010-01-20 Fujifilm Mfg Europe Bv Anti-fibrotic hydrogel compositions
JP2013514093A (en) 2009-12-16 2013-04-25 バクスター・インターナショナル・インコーポレイテッド Hemostatic sponge
GB201001203D0 (en) * 2010-01-25 2010-03-10 Anamar Medical Ab Use of pharmaceutically active compounds
SA111320355B1 (en) 2010-04-07 2015-01-08 Baxter Heathcare S A Hemostatic sponge
KR101003331B1 (en) 2010-05-11 2010-12-23 조강선 Dermal filler composition
CN103037845B (en) 2010-06-01 2015-11-25 巴克斯特国际公司 For the preparation of the method for dry, stable hemostatic composition
US9084728B2 (en) 2010-06-01 2015-07-21 Baxter International Inc. Process for making dry and stable hemostatic compositions
JP6289096B2 (en) 2010-06-01 2018-03-07 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Process for making a dry and stable hemostatic composition
HUE044196T2 (en) * 2010-07-16 2019-10-28 Tx Medic Ab Cell therapy
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
JP6042815B2 (en) 2010-10-08 2016-12-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications
EP2637707A4 (en) 2010-11-09 2014-10-01 Kensey Nash Corp Adhesive compounds and methods use for hernia repair
FR2972626B1 (en) 2011-03-16 2014-04-11 Sofradim Production PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED
EP2694120A1 (en) * 2011-04-07 2014-02-12 Allergan, Inc. Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture
US9567357B2 (en) 2011-06-24 2017-02-14 Biointeractions Ltd. Biocompatible, biomimetic ampholyte materials
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
FR2977789B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
FR2977790B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
WO2013046058A2 (en) 2011-09-30 2013-04-04 Sofradim Production Reversible stiffening of light weight mesh
AU2012318257B2 (en) 2011-10-11 2015-10-01 Baxter Healthcare S.A. Hemostatic compositions
US20130090291A1 (en) 2011-10-11 2013-04-11 Baxter Healthcare S.A. Hemostatic compositions
US20130108671A1 (en) 2011-10-27 2013-05-02 Baxter Healthcare S.A. Hemostatic compositions
WO2013067195A1 (en) * 2011-11-02 2013-05-10 Halscion, Inc. Methods and compositions for wound treatment
CA2857306C (en) 2011-12-02 2017-07-25 Acufocus, Inc. Ocular mask having selective spectral transmission
BR112014015940B1 (en) 2011-12-28 2022-08-09 Galectin Therapeutics, Inc PHARMACEUTICAL GRADE POLYSACCHARIDE, COMPOSITION, AND THEIR USES
FR2985170B1 (en) 2011-12-29 2014-01-24 Sofradim Production PROSTHESIS FOR INGUINAL HERNIA
FR2985271B1 (en) 2011-12-29 2014-01-24 Sofradim Production KNITTED PICOTS
EP2612846A1 (en) 2012-01-09 2013-07-10 Bayer MaterialScience AG Beta amino acid esters and use of same
JP6241624B2 (en) 2012-03-06 2017-12-06 フェロサン メディカル デバイシーズ エイ／エス Pressurized container containing hemostatic paste
KR102071739B1 (en) 2012-06-06 2020-01-30 갈렉틴 테라퓨틱스, 인크. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
JP6394916B2 (en) 2012-06-12 2018-09-26 フェロサン メディカル デバイシーズ エイ／エス Dry hemostatic composition
FR2994185B1 (en) 2012-08-02 2015-07-31 Sofradim Production PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER
BR112015005772A2 (en) 2012-09-17 2017-08-08 Galectin Therapeutics Inc Method for Intensifying Specific Immunotherapies in Cancer Treatment
FR2995778B1 (en) 2012-09-25 2015-06-26 Sofradim Production ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME
FR2995788B1 (en) 2012-09-25 2014-09-26 Sofradim Production HEMOSTATIC PATCH AND PREPARATION METHOD
FR2995779B1 (en) 2012-09-25 2015-09-25 Sofradim Production PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION
AU2013322268B2 (en) 2012-09-28 2017-08-31 Sofradim Production Packaging for a hernia repair device
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
US9707323B2 (en) 2012-11-12 2017-07-18 Warsaw Orthopedic, Inc. Devices and methods for inhibiting adhesion formation
US9421221B2 (en) 2012-11-12 2016-08-23 Warsaw Orthopedic, Inc. Compositions and methods for inhibiting adhesion formation
CN102973593A (en) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 Application of dextran sulfate in preparing medicament for treating hepatic fibrosis
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
JO3529B1 (en) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
USRE49528E1 (en) 2013-04-26 2023-05-16 Biointeractions Ltd. Bioactive coatings
CN110776610A (en) 2013-04-26 2020-02-11 生物相互作用有限公司 Bioactive coating
FR3006581B1 (en) 2013-06-07 2016-07-22 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
FR3006578B1 (en) 2013-06-07 2015-05-29 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
CA2928963C (en) 2013-12-11 2020-10-27 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
EP3000433B1 (en) 2014-09-29 2022-09-21 Sofradim Production Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis
EP3000432B1 (en) 2014-09-29 2022-05-04 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
JP6726852B2 (en) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス Dry composition for use in hemostasis and wound healing
EP3029189B1 (en) 2014-12-05 2021-08-11 Sofradim Production Prosthetic porous knit, method of making same and hernia prosthesis
JP6747650B2 (en) 2014-12-24 2020-08-26 フェロサン メディカル デバイシーズ エイ／エス Syringe for holding and mixing the first substance and the second substance
EP3059255B1 (en) 2015-02-17 2020-05-13 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
EP3085337B1 (en) 2015-04-24 2022-09-14 Sofradim Production Prosthesis for supporting a breast structure
ES2676072T3 (en) 2015-06-19 2018-07-16 Sofradim Production Synthetic prosthesis comprising a knitted fabric and a non-porous film and method of forming it
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
SG11201800201QA (en) * 2015-07-20 2018-02-27 Bengt I Samuelsson Institute Of Life Science Res Applications of mussel adhesive protein product in treatment and prevention of diseases related to melanin
US10568938B2 (en) 2015-07-20 2020-02-25 Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd. Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2017011986A1 (en) 2015-07-20 2017-01-26 赵兵 Air filter
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
WO2017028025A1 (en) 2015-08-14 2017-02-23 江阴市本特塞缪森生命科学研究院有限公司 Mussel adhesive protein product and use thereof for inhibiting mucosal inflammation
CN108135167B (en) 2015-08-19 2021-07-09 哈佛学院院长及董事 Lipidated PSA compositions and methods
EP3195830B1 (en) 2016-01-25 2020-11-18 Sofradim Production Prosthesis for hernia repair
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3312325B1 (en) 2016-10-21 2021-09-22 Sofradim Production Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
EP3398554A1 (en) 2017-05-02 2018-11-07 Sofradim Production Prosthesis for inguinal hernia repair
US11291684B2 (en) 2017-05-17 2022-04-05 Tx Medic Ab Treatment of glaucoma
US11534457B2 (en) 2017-09-08 2022-12-27 Tx Medic Ab Use of dextran sulfate
TW201940178A (en) * 2018-01-31 2019-10-16 日商瑪路弘股份有限公司 Topical dermatological composition
JP7395113B2 (en) 2018-05-09 2023-12-11 フェロサン メディカル デバイシーズ エイ／エス Method of preparing a hemostatic composition
EP3653171A1 (en) 2018-11-16 2020-05-20 Sofradim Production Implants suitable for soft tissue repair
CA3144487C (en) * 2019-08-01 2024-01-02 Km Biologics Co., Ltd. Tissue fibrosis inhibitor in which biocompatible polymer is used
CN114870085A (en) * 2022-04-21 2022-08-09 河南亚都实业有限公司 Fish skin collagen/oyster bone induction composite material and preparation method thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE252838C (en)
DE252839C (en)
US5A (en) * 1836-08-10 Thomas blancharjq
US2715091A (en) * 1949-11-28 1955-08-09 Nat Res Dev Dextran sulfate as anticoagulant, process of preparing same, and sterile solution thereof
US3487150A (en) * 1965-10-23 1969-12-30 Cornell Res Foundation Inc Dextran sulphate treatment of peptic ulcers
US3632754A (en) * 1968-02-12 1972-01-04 Lescarden Ltd Use of chitin for promoting wound healing
US3627872A (en) * 1968-04-08 1971-12-14 Upjohn Co Oral treatment of hyper-cholesteremia in mammals and birds with ether-type anion exchangers of polysaccharides
US3914413A (en) * 1971-02-10 1975-10-21 Leslie L Balassa Process for facilitating wound healing with N-acetylated partially depolymerized chitin materials
US3847155A (en) * 1972-01-26 1974-11-12 O Bernaola Methods for the elimination of scars using copolymer films in place of surgical sutures
US4103003A (en) * 1972-09-28 1978-07-25 Ashmead H H Composition for improving biologic development
US4537767A (en) * 1973-01-29 1985-08-27 Pharmacia Aktiebolag Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method
SE452109B (en) * 1973-01-29 1987-11-16 Pharmacia Ab SCIENTIFIC CLEANER EXTENDED SARYTOR
US3886947A (en) * 1973-04-13 1975-06-03 Meadox Medicals Inc Non-thrombogenic catheter
JPS5616765B2 (en) * 1975-02-05 1981-04-18
DE2522178A1 (en) * 1975-05-17 1976-11-25 Bayer Ag GRANULES AND POWDER FOR THE MANUFACTURE OF Ointments
US4280954A (en) * 1975-07-15 1981-07-28 Massachusetts Institute Of Technology Crosslinked collagen-mucopolysaccharide composite materials
GB1506217A (en) * 1975-08-26 1978-04-05 Taiho Pharmaceutical Co Ltd Oral antilipemic composition
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4021544A (en) * 1976-07-12 1977-05-03 American Cyanamid Company Complement inhibitors
US4066829A (en) * 1976-07-12 1978-01-03 American Cyanamid Company Malto-dextrin poly(H-)sulfates
LU77562A1 (en) * 1977-06-17 1979-03-26 Ciba Geigy Ag METHOD FOR PRODUCING NEW PHARMACEUTICAL PREPARATIONS
US4321273A (en) * 1978-03-01 1982-03-23 Ryuichi Sato Germanium-containing organic polymer and its use in the treatment of pulmonary fibrosis
US4271084A (en) * 1978-03-01 1981-06-02 Ryuichi Sato Germanium-containing organic polymer and the process for the production of the same
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2440376A1 (en) * 1978-11-06 1980-05-30 Choay Sa MUCOPOLYSACCHARIDIC COMPOSITION HAVING REGULATORY COAGULATION ACTIVITY, MEDICAMENT CONTAINING SAME AND METHOD FOR OBTAINING SAME
US4232077A (en) * 1979-02-22 1980-11-04 Fritz Meisel Hot-stamping film, and process and apparatus for its manufacture
DE2925009A1 (en) * 1979-06-21 1981-01-08 Basf Ag PREPARATION FOR SUBSTANCES, METHOD FOR THE PRODUCTION AND USE THEREOF
FR2461724A1 (en) * 1979-07-20 1981-02-06 Christine Fougnot GROUP-SUBSTITUTED POLYMERS CONFERRING THEM WITH ANTI-COAGULANT PROPERTIES AND METHOD FOR THE PREPARATION THEREOF, OBJECTS CONSISTING OF AND / OR COMPRISING THE SAID POLYMERS AND METHODS OF MAKING THEM, APPLICATION OF SAID OBJECTS IN SURGERY AND MEDICINE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID SUBSTITUTED POLYMERS
US4618490A (en) * 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
JPS5885813A (en) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd Drug preparation having high absorbability
US4793336A (en) * 1981-03-25 1988-12-27 Wang Paul Y Wound coverings and processes for their preparation
FR2535324A1 (en) * 1982-10-27 1984-05-04 Choay Sa PERFECTED STATION FOR THE PURIFICATION OF WASTEWATER
US4350629A (en) * 1981-07-29 1982-09-21 Massachusetts Institute Of Technology Procedures for preparing composite materials from collagen and glycosaminoglycan
US4625016A (en) * 1981-10-16 1986-11-25 University Of Medicine And Dentistry Of New Jersey Collagen inhibiting compositions and processes for manufacturing and using same
US4428939A (en) * 1981-10-16 1984-01-31 Prockop Darwin J Collagen inhibiting compositions and processes for manufacturing and using same
US4672031A (en) * 1981-10-16 1987-06-09 University Of Medicine And Dentistry Of New Jersey Method of treating the effectiveness of collagen-inhibiting compositions
DE3305047A1 (en) * 1982-02-19 1983-09-22 Terumo Kabushiki Kaisha trading as Terumo Corp., Tokyo POLYSACCHARIDES, THEIR PRODUCTION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US4538603A (en) * 1982-04-22 1985-09-03 E. R. Squibb & Sons, Inc. Dressings, granules, and their use in treating wounds
US4728642A (en) * 1982-04-22 1988-03-01 E. R. Squibb & Sons, Inc. Method of treating wounds with granules and dressing
CA1212879A (en) * 1982-07-21 1986-10-21 Laszlo Juhasz Composite wound dressing
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
JPS6028936A (en) * 1983-07-27 1985-02-14 Koken:Kk Atherocollagen aqueous solution and its preparation
SE8304836D0 (en) * 1983-09-09 1983-09-09 Pharmacia Ab SETTLE TO DETERMINE CHANGES IN LEDS
US4448718A (en) * 1983-09-13 1984-05-15 Massachusetts Institute Of Technology Method for the preparation of collagen-glycosaminoglycan composite materials
GB2150833B (en) * 1983-12-08 1987-04-15 Ceskoslovenska Akademie Ved Proteolytic wounds dressing
US4837024A (en) * 1984-02-24 1989-06-06 The Regents Of The University Of California Compositions, articles and mehtod for improving wound healing
US4808570A (en) * 1984-02-24 1989-02-28 University Of California Compositions and method for improving wound healing
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
US4496397A (en) * 1984-03-07 1985-01-29 University Of Connecticut Process for purifying and stabilizing catechol-containing proteins and materials obtained thereby
US4687740A (en) * 1984-03-07 1987-08-18 University Of Connecticut Research & Development Corp. Decapeptides produced from bioadhesive polyphenolic proteins
US4585585A (en) * 1984-03-07 1986-04-29 University Of Connecticut Research & Development Corporation Decapeptides produced from bioadhesive polyphenolic proteins
CA1295796C (en) * 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
US4925924A (en) * 1984-03-27 1990-05-15 University Of Medicine And Dentistry Of New Jersey Biocompatible synthetic and collagen compositions having a dual-type porosity for treatment of wounds and pressure ulcers and therapeutic methods thereof
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
SE456346B (en) * 1984-07-23 1988-09-26 Pharmacia Ab GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION
US4710493A (en) * 1984-08-14 1987-12-01 Albert Landsberger Therapeutic agent for the use in cancer treatment
US4820303A (en) * 1984-08-30 1989-04-11 Daniel Brauman Implantable prosthetic devices
GB8430265D0 (en) * 1984-11-30 1985-01-09 Vascutek Ltd Vascular graft
US4773408A (en) * 1985-01-04 1988-09-27 E. R. Squibb & Sons, Inc. Wound dressing
US4773409A (en) * 1985-09-20 1988-09-27 E. R. Squibb & Sons, Inc. Wound dressing
IT1208509B (en) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl PROCESS FOR THE PRODUCTION OF NATURALLY PURE NATURAL EPARAN SULPHATE AND DERMATAN SULPHATE AND THEIR PHARMACEUTICAL USE.
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US4659572A (en) * 1985-04-15 1987-04-21 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Burn wound dressing material
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4713446A (en) * 1985-09-06 1987-12-15 Minnesota Mining And Manufacturing Company Viscoelastic collagen solution for ophthalmic use and method of preparation
US4908350A (en) * 1985-10-31 1990-03-13 The Regents Of The University Of California Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock
JPH0663187B2 (en) * 1985-12-23 1994-08-17 東京製鋼株式会社 Steel cord for reinforcing plastics
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DE3601136A1 (en) * 1986-01-16 1987-07-23 Max Planck Gesellschaft INHIBITORS OF REVERSE TRANSCRIPTASE FOR PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS IN MAMMALS
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
AU600271B2 (en) * 1986-04-04 1990-08-09 Angiogenics Ltd Composition for arresting angiogenesis and capillary, cell or membrane leakage
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
JPS6323670A (en) * 1986-04-25 1988-01-30 バイオ−ポリマ−ズ　インコ−ポレ−テツド Adhesive coating composition and its production
US5112608A (en) * 1987-03-13 1992-05-12 Incyte Pharmaceuticals Use of protease nexin-I to mediate wound healing
US5196196A (en) * 1986-06-03 1993-03-23 Incyte Pharmaceuticals, Inc. Use of protease nexin-I in wound dressings
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
JPS6357522A (en) * 1986-08-28 1988-03-12 Mect Corp Inhibitor of blood platelet aggregation consisting of pyrimido(2,1-d)benzothiazole derivative
DD252838A1 (en) * 1986-09-25 1987-12-30 Thueringen Gummiwerke Veb METHOD FOR PRODUCING LATEX ARTICLES WITH ANTICOAGULATIVE DEPOT EFFECT
DD252839A1 (en) * 1986-09-25 1987-12-30 Thueringen Gummiwerke Veb METHOD FOR PRODUCING LATEX ARTICLES WITH ANTICOAGULATIVE DEPOT EFFECT
DE3634392A1 (en) * 1986-10-09 1988-04-14 Knoll Ag USE OF POLYSULFATED LOW MOLECULAR DEXTRANSULFATES
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
JPH02501706A (en) * 1986-11-24 1990-06-14 ジェネックス・コーポレーション biological adhesive
JPH021287A (en) 1986-12-25 1990-01-05 Terumo Corp Bio-compatible material, medical material and microcapsule using the same and preparation thereof
DE3705669A1 (en) * 1987-02-21 1988-09-01 Thomae Gmbh Dr K USE OF DEXTRANSULFATE FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND PROPHYLAXIS OF VESSEL NARROWS AND VESSEL CLOSURES
AU1572588A (en) * 1987-03-12 1988-10-10 Genex Corp. Production of bioadhesive precursor protein analogs by genetically-engineered organisms
AU606410B2 (en) * 1987-03-13 1991-02-07 Brown University Research Foundation Piezoelectric nerve guidance channels
DE3709101A1 (en) * 1987-03-20 1988-09-29 Mueller Lierheim Kg Biolog Lab IMMOBILIZATION SUBSTANCE
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
US4927806A (en) * 1987-04-23 1990-05-22 The Regents Of The University Of California Saturated salt/concentrated dextran formulation to treat hemorrhage
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
FR2616318A1 (en) 1987-06-15 1988-12-16 Centre Nat Rech Scient ARTIFICIAL SKIN AND PROCESS FOR PREPARING THE SAME
US4882148A (en) * 1987-06-18 1989-11-21 Corvita Corporation Crack prevention and improved thrombogenicity of implanted prostheses by sulfonation
US4880429A (en) * 1987-07-20 1989-11-14 Stone Kevin R Prosthetic meniscus
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
IT1217458B (en) * 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S SULFOAMINO DERIVATIVES OF CONDROITIN SULPHATES, DERMATAN SULPHATE AND HYALURONIC ACID AND THEIR PHARMACOLOGICAL PROPERTIES
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
FR2635327B1 (en) * 1988-08-10 1990-11-16 Guerbet Sa IODINE POLYMERS WITH DEXTRAN SKELETON, METHODS OF PREPARING THEM AND APPLICATIONS THEREOF AS CONTRAST PRODUCTS
JPH0296588A (en) * 1988-09-29 1990-04-09 Rikagaku Kenkyusho Sulfated oligosaccharide and relating substance thereof
AU629259B2 (en) * 1988-10-27 1992-10-01 University Of Kentucky Research Foundation, The Human leukocyte elastase inhibitors and methods of producing and using same
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
KR910700063A (en) * 1988-12-20 1991-03-13 알. 더글라스 암스트롱 Polypeptide-polymer conjugates having wound healing activity
DE3902021A1 (en) * 1989-01-20 1990-07-26 Entec USE OF ANTIPEPTIDERGENS, IF NECESSARY IN COMBINATION WITH ANTI-ANDROGEN AGENTS, FOR THE TREATMENT OF HUMAN PROSTATE CARCINOMA
SE8900586L (en) * 1989-02-21 1990-08-22 Pharmacia Ab COMPOSITION AND PROCEDURES TO PREVENT ADHESION BETWEEN BODY TISSUE
NL8900442A (en) * 1989-02-22 1990-09-17 Stichting Rega V Z W SULFATED VINYL POLYMERS IN MEDICINES FOR TREATING RETROVIRUS INFECTIONS.
US5196185A (en) * 1989-09-11 1993-03-23 Micro-Collagen Pharmaceutics, Ltd. Collagen-based wound dressing and method for applying same
US5213898A (en) * 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5049403A (en) * 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
WO1991006303A1 (en) * 1989-10-27 1991-05-16 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5459054A (en) * 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
WO1991011205A1 (en) * 1990-01-23 1991-08-08 Trancel Corporation Mannuronic acid containing alginate wound healing composition and method
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
AU647484B2 (en) * 1990-04-26 1994-03-24 Cytrx Corporation Composition and method for topical treatment of damaged or diseased tissue
US5120322A (en) * 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5209776A (en) * 1990-07-27 1993-05-11 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
DE4039867A1 (en) 1990-12-13 1992-06-17 Diagen Inst Molekularbio Agent for prophylaxis and therapy of viral infections - comprises antiviral substances and/or polyanions in physiologically acceptable carrier particles
CZ232593A3 (en) 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
FI943810A (en) 1994-08-19 1996-02-20 Bretec Oy Hydraulic hammer
US5981509A (en) 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
WO1999000417A1 (en) 1997-06-25 1999-01-07 Novo Nordisk A/S Production of heparin-binding protein in mammalian cells
EP1054664B1 (en) 1998-02-11 2012-08-08 BHI Limited Partnership Method for modulating macrophage activation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution

Also Published As

Publication number Publication date
JP3379757B2 (en) 2003-02-24
AU2146992A (en) 1993-01-08
FI935345A (en) 1994-01-13
EP0586535B1 (en) 2000-11-22
DE1027893T1 (en) 2001-09-20
JP3923290B2 (en) 2007-05-30
ATE297212T1 (en) 2005-06-15
GR3034760T3 (en) 2001-02-28
BG98333A (en) 1994-12-02
CA2110291C (en) 2009-10-13
JPH06508356A (en) 1994-09-22
NO305974B1 (en) 1999-08-30
DE69233527D1 (en) 2005-07-14
HUT66427A (en) 1994-11-28
DE69231574T2 (en) 2001-05-31
US20030069205A1 (en) 2003-04-10
DK0586535T3 (en) 2001-03-05
US5605938A (en) 1997-02-25
NO934319D0 (en) 1993-11-29
US6020326A (en) 2000-02-01
US6127348A (en) 2000-10-03
EP1038528B1 (en) 2005-06-08
DE69231574D1 (en) 2000-12-28
EP1038528A1 (en) 2000-09-27
AU671256B2 (en) 1996-08-22
EP1027893B1 (en) 2008-12-31
EP1027893A2 (en) 2000-08-16
JP2002138040A (en) 2002-05-14
ES2151887T3 (en) 2001-01-16
SK134393A3 (en) 1994-08-10
JP2002154972A (en) 2002-05-28
US5994325A (en) 1999-11-30
GR20010300032T1 (en) 2001-06-29
US6756362B2 (en) 2004-06-29
JP2002154973A (en) 2002-05-28
DE1038528T1 (en) 2001-09-20
BR9206077A (en) 1994-11-15
US5705177A (en) 1998-01-06
ATE418993T1 (en) 2009-01-15
US6417173B1 (en) 2002-07-09
WO1992021354A1 (en) 1992-12-10
JP2002138039A (en) 2002-05-14
KR100237731B1 (en) 2000-02-01
EP0586535A1 (en) 1994-03-16
DE69233753D1 (en) 2009-02-12
EP0586535A4 (en) 1994-12-07
NO934319L (en) 1994-01-11
FI935345A0 (en) 1993-11-30
US6083930A (en) 2000-07-04
JP2000312715A (en) 2000-11-14
EP1027893A3 (en) 2003-01-02
CZ259493A3 (en) 1994-11-16
ATE197673T1 (en) 2000-12-15
ES2156839T1 (en) 2001-08-01
ES2156840T1 (en) 2001-08-01
GR20010300031T1 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
CA2110291A1 (en) Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US6464970B1 (en) Method and composition for preventing surgical adhesions
US6086907A (en) Method and composition for preventing surgical adhesions
US5350573A (en) Method and composition for preventing surgical adhesions
Ljungberg et al. Neuronal survival using a resorbable synthetic conduit as an alternative to primary nerve repair
CA2126087A1 (en) Composite membranes for the guided regeneration of tissues
CA2118219A1 (en) Preparations of low molecular weight hyaluronic acid for stimulating bone formation
WO2001039795A3 (en) Attenuation of fibroblast proliferation
Zahir et al. Ischemic preconditioning of musculocutaneous flaps: effects of ischemia cycle length and number of cycles
CA1341093C (en) Method and composition for preventing surgical adhesions
US8158610B2 (en) Dextrin-containing composition for preventing surgical adhesions
AU740832B2 (en) Dextrin-containing composition for preventing surgical adhesions
CA2097268A1 (en) Absorbable bone sealant
EP1839671A3 (en) Attenuation of fibroblast proliferation
Sevo et al. Interactive effect of calcium stearate, supplier process, sterilization, and accelerated aging on UHMWPE

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20120529